CYP cynata therapeutics limited

9.68%

17.0¢

Ann: Letter to Shareholders, Notice of AGM & Proxy Form, page-5

First 5 Last

Share
Profile

Follow
Pledge

8,725 Posts.

1455

25/10/22

19:42

Post #: 64391630
Share

Originally posted by JB1975: ↑

Why post that in this thread?

Ok Planning is underway. That's not a commitment yet in my opinion to doing a phase 2. Its just considering it, getting ready.

There's a thing called a feasibilility study that I would do in Ross's position prior to doing a proper plan. A proper plan involving full costings. A feasibility study just quickly looks at the key success factors to see if they can be met. Like recruiting 60 in a reasonable period when others like MSB may also be trying to recruit for say a phase 4 - adult confirmation.

If you need 60 patients look at the feasibility of getting those 60 patients from specific clinics based on their historical records of treating people that end up getting GVHD.

If you can't find 60 patients to be a likely gettable number from a doable number of clinics in a variety of countries including the US, Australia, Canada and some others then you don't start the trial.

Before full planning there is planning the plan. A feasibility study is a right sized approach - not in my opinion opening an office in the US as you've suggested that is an expense that has to be justified. Maybe it would be justified if it was necessary to build relationships with clinics in the US - maybe that is why SI has an office in the US rather than that the FDA needed him to.

Expand

I copied it from the announcement. The announcement on this thread.

It's new.

That's why.

As to the rest of the 'stuff' you wrote, you're putting the cart before the horse.

Where's the cash to do the trial?

It's been talked up since Oct 2021.

CYP Price at posting: 32.0¢ Sentiment: None Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

AII

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

OCC

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

MVF

Monash IVF shares cater 25% – Disaster or deep-value play?

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

SRL

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

First 5 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 17.0¢		Change 0.015(9.68%)		Mkt cap ! $38.41M

Open	High	Low	Value	Volume
15.5¢	17.0¢	15.5¢	$47.10K	289.1K

Buyers (Bids)

No.	Vol.	Price($)
1	50000	16.5¢

Sellers (Offers)

Price($)	Vol.	No.
17.0¢	23813	3

View Market Depth

No.	Vol.	Price($)
1	50000	0.165
4	47240	0.155
4	161673	0.150
1	5000	0.145
2	45000	0.140

Price($)	Vol.	No.
0.170	18813	2
0.175	55250	1
0.180	62619	3
0.185	35990	1
0.195	19300	1

Last trade - 16.10pm 27/06/2025 (20 minute delay)

CYP (ASX) Chart

Ann: Letter to Shareholders, Notice of AGM & Proxy Form, page-5

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Monash IVF shares cater 25% – Disaster or deep-value play?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Letter to Shareholders, Notice of AGM & Proxy Form, page-5

Top Stories

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Week 26 Wrap: Renewable gas fantasies; RBA July cut hope builds; copper's August peak?

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Orthocell sees 4% jump as Remplir used in first US surgery. But is that low?

Monash IVF shares cater 25% – Disaster or deep-value play?

Australia’s gas crisis is here – and dying coal plants aren’t helping

Sunrise pops on top scandium hits NSW explorer will now use for 'multi-decade' plan

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

HotCopper Highlights Week 26: Droneshield 2.0; Trigg re-jig & Virgin

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News